A French LCH cohort demonstrated that 89.2% of patients with hepatic LCH carried a BRAF V600E mutation, which is related to activation of the MAPK pathway, increased resistance to first-line treatment and increased reactivation [14]. The gene discussed is BRAF; the disease is Langerhans cell histiocytosis.